Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens
MWN-AI** Summary
Alpha Cognition Inc. (NASDAQ: ACOG) has announced the issuance of a new U.S. patent, U.S. Patent Application No. 12,551,491, by the United States Patent and Trademark Office (USPTO). This patent, titled “Dosage Regimens for Benzgalantamine,” encompasses methods for orally delivering benzgalantamine aimed at treating mild to moderate Alzheimer’s disease, with patent protection extending through July 2045. The patent significantly bolsters Alpha Cognition's intellectual property portfolio, particularly supporting its FDA-approved therapy, ZUNVEYL, designed for Alzheimer’s patients.
According to CEO Michael McFadden, the patent adds substantial protection by covering specific dosing regimens that enhance ZUNVEYL’s differentiation in the market and enhance its commercial value in the U.S. This development aligns with Alpha Cognition’s long-term intellectual property strategy, safeguarding crucial administration methods for benzgalantamine and extending exclusivity beyond current protections.
ZUNVEYL is characterized as a next-generation acetylcholinesterase inhibitor with a unique action mechanism, particularly its active metabolite’s ability to bind to neuronal nicotinic receptors to potentially improve cognitive function with minimal gastrointestinal side effects. The company is also developing ALPHA-1062 in conjunction with memantine for treating moderate to severe Alzheimer’s dementia, and as an intranasal formulation targeting cognitive impairment related to mild traumatic brain injury.
This announcement comes amidst the backdrop of various risks associated with the commercialization of ZUNVEYL, including regulatory challenges, market adoption hurdles, and potential product liability issues. Forward-looking statements within the release indicate the company's cautious optimism about ZUNVEYL’s prospects, but also highlight uncertainties that could affect its actual outcomes.
MWN-AI** Analysis
Alpha Cognition Inc. (NASDAQ: ACOG) has recently made a significant move that could bolster its market position with the issuance of a new U.S. patent covering formulative dosing regimens for benzgalantamine, the active compound in ZUNVEYL, its recently FDA-approved treatment for mild to moderate Alzheimer's disease. This patent not only extends the exclusivity of ZUNVEYL until July 2045 but also strengthens the company's intellectual property (IP) portfolio—a key factor in the biopharmaceutical industry.
Investors should perceive this development positively, as robust patent protection is instrumental in building a solid competitive advantage and enhancing the commercial viability of ZUNVEYL. The patent's focus on specific dosing regimens addresses clinicians' practical concerns, potentially improving patient adherence and outcomes, thereby elevating the drug’s market appeal.
Moreover, the Alzheimer's treatment market remains substantial and underexploited, given the limited options currently available for patients. ZUNVEYL’s unique mode of action—binding to neuronal nicotinic receptors, particularly the alpha-7 subtype—sets it apart from competitors like donepezil and rivastigmine, emphasizing its innovative edge.
However, investors should remain cautious. While the patent enhances market positioning, Alpha Cognition still faces challenges in securing consistent market adoption and ensuring the continued efficacy and safety of ZUNVEYL. Regulatory scrutiny and product liability risks are significant factors that could impact future performance.
In summary, ACOG's recent patent issuance is a strategic win that could enhance long-term value for investors. However, potential stakeholders should closely monitor not only the firm's ability to navigate the commercialization complexities but also the evolving landscape in neurological treatment options. Overall, a cautious optimism is warranted as ACOG capitalizes on this new development within a dynamically growing industry.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled “Dosage Regimens for Benzgalantamine.”
The issued patent includes claims covering methods of orally administering benzgalantamine for the treatment of mild to moderate Alzheimer’s disease using specific dosing regimens. The patent is expected to provide U.S. patent protection through July 2045 and represents an important addition to the Company’s intellectual property portfolio supporting ZUNVEYL, Alpha Cognition’s FDA-approved therapy for mild to moderate Alzheimer’s disease.
“This newly issued patent meaningfully strengthens the intellectual property protection surrounding ZUNVEYL by covering clinically relevant dosing regimens for oral administration,” said Michael McFadden, Chief Executive Officer of Alpha Cognition. “These method-of-use claims extend and reinforce our existing patent portfolio, supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value in the U.S. market.”
The issuance of this patent further advances Alpha Cognition’s long-term intellectual property strategy by protecting key methods of administering benzgalantamine and extending exclusivity beyond existing patent coverage. The Company believes this patent underscores the innovative nature of its benzgalantamine research and supports durable market protection for ZUNVEYL.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a pre-commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.
This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward?looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward?looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward?looking statements may include statements regarding the Company’s expectation that the additional U.S. patent will provide U.S. patent protection through July 2045 and supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value and protecting key methods of administering benzgalantamine, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital, including bridge funding, to implement our plans to commercialize ZUNVEYL , risks regarding the efficacy and tolerability of ZUNVEYL , risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL , risks related to the Company’s intellectual property in relation to ZUNVEYL , risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL , risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K as filed with the SEC on March 31, 2025 and available at www.sec.gov . These forward?looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward?looking statements for any reason, even if new information becomes available in the future, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260218956050/en/
Investor Relations
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ**
How does the newly issued U.S. Patent Application No. 12,551,491 for Alpha Cognition Inc. (ACOG) further differentiate ZUNVEYL from other Alzheimer’s treatments currently available on the market?
What specific clinical data or studies will Alpha Cognition Inc. (ACOG) leverage to demonstrate the efficacy and safety of the newly patented dosing regimens for benzgalantamine?
Given the issued patent for Alpha Cognition Inc. (ACOG) extends exclusivity through July 2045, how does the company plan to capitalize on this extended protection to enhance commercial value for ZUNVEYL?
What are the key milestones and timelines that Alpha Cognition Inc. (ACOG) expects to achieve in the commercialization process for ZUNVEYL and the ongoing development of ALPHA-1062?
**MWN-AI FAQ is based on asking OpenAI questions about Alpha Cognition Inc. (NASDAQ: ACOG).
NASDAQ: ACOG
ACOG Trading
0.17% G/L:
$5.81 Last:
55,260 Volume:
$5.89 Open:
